

CURRICULUM VITAE

PERSONAL INFORMATION

First Name	Ioannis
Last Name	Boukovinas
Year of Birth	1959

HOSPITAL ADDRESS (Current Position)

Hospital	Bioclinic Thessaloniki		
Department	Oncology Department		
Address	86 Mitropoleos St.		
Postal Code	54622		
City	Thessaloniki		
Country	Greece		
Telephone Number	+302310372698	Fax Number	+302310372698
Mobile	+306944189715		
E-mail Address	ibouk@otenet.gr		
Medical License Number	42913 (dated: 26/09/1988)		
State/Region/Province	Prefecture of Thessaloniki		
Expiration Date	Indefinitely		

ACADEMIC QUALIFICATIONS

Degree	PhD - Adenocarcinoma of lung cancer and prediction of successful treatment accordingly to RRM1/RRM2/BRCA1		
Institution	University of Crete, Greece	Date	2011
Degree	Diplome d'Universite Europeene on Cancer hepato-bilaire-pancreatique: approche onco-chirurgicale		
Institution	University of Paris XI, France	Date	2004-2006
Degree	Medical Oncologist		
Institution	2 nd Oncology Dpt. Theagenion Cancer Hospital, Thessaloniki, Greece	Date	2000
Degree	Internist		
Institution	2 nd Oncology Dpt. Theagenion Cancer Hospital, Thessaloniki, Greece	Date	1997
Degree	Medicine (Excellent)		
Institution	Aristotle University of Thessaloniki, Greece	Date	1982-1988
Degree	Pharmacology (Very good)		
Institution	Aristotle University of Thessaloniki, Greece	Date	1976-1980

PROFESSIONAL EXPERIENCE

Position held	Name of Department / Institution	Date
Head of Oncology Department	Thessaloniki Bioclinic, Greece	2013-today
Consultant Medical Oncologist	2 nd Medical-Oncology Dpt., Theagenion Cancer Hospital, Thessaloniki	2000- 2013
Consultant Medical Oncologist	Institut Gustave-Roussy, Paris	2001-2002
Scientific Collaborator in the	2 nd Oncology Dpt, Theagenion Cancer Hospital, Thessaloniki	1997- 2000
Resident in Internal Medicine	Theagenion Cancer Hospital, Hippokration General Hospital, Thessaloniki	1992-1997
Resident in Paediatrics	Kilkis General Hospital, Greece	1990-1992
Rural physician	Alexandria, Greece	1988-1990

PROFESSIONAL SOCIETY MEMBERSHIPS

Member of ESMO Sarcoma Faculty 2008-2023
President of EOSSO 2019-2023
President of Society of Oncology Diaspora 2022
Board of Directors of the Hellenic Society of Medical Oncologists 2011-2017 / President 2017-2021
Member of European Society of Medical Oncologists 2001
Member of American Society of Medical Oncologists (in Good Standing)

EORTC Soft Tissue & Bone Sarcoma Group
Member of Society of Hellenic Internists
Member of Society of Hellenic Nephrologists
Member of Medical Society of Thessaloniki

VOLUNTEERING-HUMANITARIAN AID

Role	Organization	Date
Guest speaker in annual seminars	'Alma Zois' Breast Cancer Association	2016-2023
Co-founder / Mission delegate Vice-president for 4 years	Medecins du Monde - Grece, Humanitarian non- governmental Organization	1990-2000
Consultant	European Union ROMA programs in Greece and Slovakia	1990-2000

LANGUAGES

Language	Fluency / Degree
French	Proficient
English	Proficient
Greek	Native

GOOD CLINICAL PRACTICE (GCP)

Duration	2 hours		
Title / Content	ICH GOOD CLINICAL PRACTICE E6 (R2)		
Provider	The Global Health Network	Online training:	✓
Date of Training Certificate	30 May 2022		

MOST CURRENT CLINICAL TRIAL EXPERIENCE

Study Name or Code	Role in the study	Therapeutic Area	Clinical Phase	Study Status
BA3021-001	PRINCIPAL INVESTIGATOR	LUNG CANCER	II/III	IN PROGRESS
C4221016	PRINCIPAL INVESTIGATOR	MEANOMA	III	IN PROGRESS
GO42784	PRINCIPAL INVESTIGATOR	BREAST CANCER	III	IN PROGRESS
1403-008 BI	PRINCIPAL INVESTIGATOR	LIPOSARCOMA	II/III	IN PROGRESS
ZWI-ZW25-301	PRINCIPAL INVESTIGATOR	GASTRIC CANCER	III	IN PROGRESS
NANORAY	PRINCIPAL INVESTIGATOR	HEAD & NECK	III	IN PROGRESS
17000139BLC2001	PRINCIPAL INVESTIGATOR	UROTHELIAL CANCER	II	IN PROGRESS
17000139BLC3001	PRINCIPAL INVESTIGATOR	UROTHELIAL CANCER	III	IN PROGRESS
20210096	PRINCIPAL INVESTIGATOR	GASTRIC CANCER	III	IN PROGRESS
M14-239	PRINCIPAL INVESTIGATOR	LUNG CANCER	II	IN PROGRESS
Glaxo 213400	PRINCIPAL INVESTIGATOR	LUNG CANCER	III	IN PROGRESS
IMMU-132-13	PRINCIPAL INVESTIGATOR	LUNG CANCER	III	IN PROGRESS
20120325	PRINCIPAL INVESTIGATOR	MELANOMA	II	IN PROGRESS
MK3475048	PRINCIPAL INVESTIGATOR	HEAD AND NECK	III	IN PROGRESS
20110265	PRINCIPAL INVESTIGATOR	MELANOMA	III	IN PROGRESS
GO29431	PRINCIPAL INVESTIGATOR	LUNG CANCER	III	IN PROGRESS
MO29112	PRINCIPAL INVESTIGATOR	COLORECTAL CANCER	II	IN PROGRESS
CA209-172	PRINCIPAL INVESTIGATOR	MELANOMA	II	COMPLETED
20120286	PRINCIPAL INVESTIGATOR	COLORECTAL CANCER	IV	COMPLETED
CBKM123F2303	PRINCIPAL INVESTIGATOR	BREAST CANCER	III	COMPLETED
20120249	PRINCIPAL INVESTIGATOR	LUNG CANCER	II	COMPLETED
20120214	PRINCIPAL INVESTIGATOR	BREAST CANCER	IV	COMPLETED
1200.247	PRINCIPAL INVESTIGATOR	LUNG CANCER	IV	COMPLETED
BEYOND-NIS-GEN-TRA-001	PRINCIPAL INVESTIGATOR	SARCOMA	IV	COMPLETED

BRF115532	PRINCIPAL INVESTIGATOR	MELANOMA	III	IN PROGRESS
CA224047	PRINCIPAL INVESTIGATOR	MELANOMA	III	COMPLETED
D133FR00126	PRINCIPAL INVESTIGATOR	LUNG CANCER	IV	IN PROGRESS
I3Y-MC-JPCF	PRINCIPAL INVESTIGATOR	BREAST CANCER	III	COMPLETED
R2810-ONC-1624	PRINCIPAL INVESTIGATOR	LUNG CANCER	III	COMPLETED
CO39722	PRINCIPAL INVESTIGATOR	MELANOMA	III	COMPLETED
CPDR001F2301	PRINCIPAL INVESTIGATOR	MELANOMA	III	COMPLETED
CDRB436F2410	PRINCIPAL INVESTIGATOR	MELANOMA	III	COMPLETED
GLOW 8951-CL-0302	PRINCIPAL INVESTIGATOR	STOMACH	III	IN PROGRESS
DS 8201-A-U303	PRINCIPAL INVESTIGATOR	BREAST CANCER	III	COMPLETED
NEKTAR 18-214-10 CA045-012	PRINCIPAL INVESTIGATOR	UROTHELIAL CANCER	II	COMPLETED
RAD 1901-308	PRINCIPAL INVESTIGATOR	BREAST CANCER	III	IN PROGRESS
20180115	PRINCIPAL INVESTIGATOR	MELANOMA	II	IN PROGRESS
TAK-788-3001	PRINCIPAL INVESTIGATOR	LUNG CANCER	III	IN PROGRESS
R2810-ONC-16113	PRINCIPAL INVESTIGATOR	LUNG CANCER	III	COMPLETED
20190009	PRINCIPAL INVESTIGATOR	LUNG CANCER	III	COMPLETED
20-214-29/CA045-022	PRINCIPAL INVESTIGATOR	MELANOMA	III	COMPLETED
GSK 209229	PRINCIPAL INVESTIGATOR	HEAD AND NECK	III	IN PROGRESS
20170734	PRINCIPAL INVESTIGATOR	COLORECTAL CANCER	IV	COMPLETED
20180020	PRINCIPAL INVESTIGATOR	BREAST CANCER	IV	COMPLETED
20190294	PRINCIPAL INVESTIGATOR	LUNG CANCER	0	IN PROGRESS
I3Y-MC-JPCW	PRINCIPAL INVESTIGATOR	BREAST CANCER	3	COMPLETED
RPL-002-18	PRINCIPAL INVESTIGATOR	CUTANEOUS SQUAMOUS CELL CA	2	IN PROGRESS
YH25448-301	PRINCIPAL INVESTIGATOR	LUNG CANCER	3	COMPLETED

MOST RECENT PUBLICATIONS

Publication Date	Title / Content
Feb 2023	Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Jan 2023	Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers.
Dec 2022	Genetic Predisposition to Male Breast Cancer: A Case Series.
Nov 2022	Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry.
Sep 2022	Prognostic Significance of Low HER2 Expression in Patients With Metastatic Hormone Receptor-positive Breast Cancer Treated With First Line CDK4/6 Inhibitors: A Greek Multicenter Real-world Data Analysis.
Jul 2022	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Jul 2022	"One Shot" Sample Evaluation of 22G, 22G upgraded, 21G and 19G needle for Endobronchial Ultrasound-EBUS-TBNA.
Apr 2022	A Multicenter, Prospective, Observational Study to Assess the Clinical Activity and Impact on Symptom Burden and Patients' Quality of Life in Patients with Advanced Soft Tissue Sarcomas Treated with Trabectedin in a Real-World Setting in Greece.
Apr 2022	Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence.
Mar 2022	Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastroesophageal junction, among patients previously treated in Greece.
Mar 2022	Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy.
Feb 2022	Treatment pathways and associated costs of metastatic colorectal cancer in Greece.
Feb 2022	Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group.
Jan-Feb 2022	Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients.
Jan 2022	Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Dec 2021	Vaccine third dose and cancer patients: necessity or luxury?

Dec 2021	Brain Metastases from Adult Sarcomas: A Retrospective Cohort Study from the Hellenic Group of Sarcomas and Rare Cancers (HGSRC).
Dec 2021	Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up
Dec 2021	Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin.
Nov 2021	Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Jun 2021	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts.
Nov 2021	Biopsy and re-biopsy for PD-L1 expression in NSCLC. association between PD-L1 and checkpoint inhibitor efficacy through treatment in NSCLC. A pilot study.
Dec 2020	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
Aug 2020	Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group
2020	Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece
Jul 2020	Real-World Data on Thromboprophylaxis in Active Cancer Patients: Where Are We? Are We Getting There?
Sep 2019	Second primary melanomas in a cohort of 977 melanoma patients within the first 5 years of monitoring.
Nov 2018	Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group.
Oct 2018	Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Oct 2018	Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Mar 2018	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Feb 2018	Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group.
Dec 2017	Tumor molecular profiling of NSCLC patients using next generation sequencing.
Jul 2017	Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.
Oct 2016	Clinical practice guidelines for the management of metastatic colorectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO).
Oct 2016	Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Apr 2016	Clinical practice guidelines for the surgical treatment of rectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO).
Jan 2016	Clinical practice guidelines for the surgical management of colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO.
Jan 2016	Adjuvant chemotherapy for colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO.
Nov 2015	The Management and Costs of Locally Advanced or Metastatic Alk-Positive Non-Small Cell Lung Cancer in Greece.
May 2015	Gastrointestinal Stromal Tumors (GIST): A Prospective Analysis and an Update on Biomarkers and Current Treatment Concepts.
Jul 2015	Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Jan 2015	Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
Dec 2014	Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research

	Group (HORG).
Nov 2014	Functional aspects of the EGF-induced MAP kinase cascade: a complex self-organizing system approach.
Nov 2014	Cost-Effectiveness Analysis of Panitumumab+Mfolfox over Bevacizumab+Mfolfox as a First-Line Treatment for Metastatic Colorectal Cancer Patients with Wild-Type Ras in Greece.
Oct 2014	Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.
Sep 2014	Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Sep 2014	Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Sep 2014	Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Apr 2014	Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Sep 2013	Neo-adjuvant chemotherapy in early stage non-small cell lung cancer.
Dec 2013	A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer.
May 2013	Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.
Oct 2012	Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Oct 2012	Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Oct 2012	Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Nov 2012	Adjuvant therapy in primary GIST: state-of-the-art.
Jan 2012	Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
Jan 2012	Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2.
May 2012	A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.
Feb 2012	Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Apr 2011	Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG).
Oct 2010	Screening of the DNA mismatch repair genes MLH1, MSH2 and MSH6 in a Greek cohort of Lynch syndrome suspected families.
Oct 2010	Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
Jan 2011	Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
May 2011	Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Aug 2010	Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Nov 2009	Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Oct 2009	eComment: The role of lymph node dissection in pulmonary resection for metastases from colorectal cancer.
Jan 2010	FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
Jan 2009	Detection of methylation in the CpG islands of the p16INK4A, RASSF 1A and methylguanine methyltransferase gene promoters in pancreatic adenocarcinoma.
Nov 2008	Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Jul 2008	A rare cause of mediastinal mass: Primary liposarcoma.
Aug 2008	Paraneoplastic pemphigus regression after thymoma resection.

Jan 2009	Treatment of non-small cell lung cancer patients with performance status2 (PS2).
Oct 2008	Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.
May 2008	Diagnosis of metastatic tumors in cerebrospinal fluid samples using thin-layer cytology.
Jan 2009	Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study.
May 2008	Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience.
May 2008	Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
Jan 2008	Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Nov 2007	Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A hellenic cooperative oncology group (HeCOG) phase II study.
Jan 2008	Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
Jan 2008	Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial.
Feb 2007	Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group.
Jan 2007	Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients.
Nov 2006	Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group.
Sep 2006	A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.
Apr 2006	Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan.
Nov 2005	Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
Oct 2005	Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study.
Aug 2004	Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial.
Aug 2004	Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
Jun 2004	A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer.
Jan 2003	[Gastro-intestinal stromal tumors: news and comments].
Sep 2002	Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial.